Cargando…
Corrigendum to: Subgroup analysis of Japanese patients in a Phase 3 study of atezolizumab in advanced triple-negative breast cancer (IMpassion130)
| Autores principales: | , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Oxford University Press
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7025717/ https://www.ncbi.nlm.nih.gov/pubmed/31950142 http://dx.doi.org/10.1093/jjco/hyz208 |
| _version_ | 1783498560271024128 |
|---|---|
| author | Iwata, Hiroji Inoue, Kenichi Kaneko, Koji Ito, Yoshinori Tsugawa, Koichiro Hasegawa, Ayumi Nakagawa, Shintaro Kuratomi, Hiroyasu Tamura, Kenji |
| author_facet | Iwata, Hiroji Inoue, Kenichi Kaneko, Koji Ito, Yoshinori Tsugawa, Koichiro Hasegawa, Ayumi Nakagawa, Shintaro Kuratomi, Hiroyasu Tamura, Kenji |
| author_sort | Iwata, Hiroji |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-7025717 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2020 |
| publisher | Oxford University Press |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-70257172020-02-20 Corrigendum to: Subgroup analysis of Japanese patients in a Phase 3 study of atezolizumab in advanced triple-negative breast cancer (IMpassion130) Iwata, Hiroji Inoue, Kenichi Kaneko, Koji Ito, Yoshinori Tsugawa, Koichiro Hasegawa, Ayumi Nakagawa, Shintaro Kuratomi, Hiroyasu Tamura, Kenji Jpn J Clin Oncol Corrigendum Oxford University Press 2020-01-17 /pmc/articles/PMC7025717/ /pubmed/31950142 http://dx.doi.org/10.1093/jjco/hyz208 Text en © The Author(s) 2020. Published by Oxford University Press. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
| spellingShingle | Corrigendum Iwata, Hiroji Inoue, Kenichi Kaneko, Koji Ito, Yoshinori Tsugawa, Koichiro Hasegawa, Ayumi Nakagawa, Shintaro Kuratomi, Hiroyasu Tamura, Kenji Corrigendum to: Subgroup analysis of Japanese patients in a Phase 3 study of atezolizumab in advanced triple-negative breast cancer (IMpassion130) |
| title | Corrigendum to: Subgroup analysis of Japanese patients in a Phase 3 study of atezolizumab in advanced triple-negative breast cancer (IMpassion130) |
| title_full | Corrigendum to: Subgroup analysis of Japanese patients in a Phase 3 study of atezolizumab in advanced triple-negative breast cancer (IMpassion130) |
| title_fullStr | Corrigendum to: Subgroup analysis of Japanese patients in a Phase 3 study of atezolizumab in advanced triple-negative breast cancer (IMpassion130) |
| title_full_unstemmed | Corrigendum to: Subgroup analysis of Japanese patients in a Phase 3 study of atezolizumab in advanced triple-negative breast cancer (IMpassion130) |
| title_short | Corrigendum to: Subgroup analysis of Japanese patients in a Phase 3 study of atezolizumab in advanced triple-negative breast cancer (IMpassion130) |
| title_sort | corrigendum to: subgroup analysis of japanese patients in a phase 3 study of atezolizumab in advanced triple-negative breast cancer (impassion130) |
| topic | Corrigendum |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7025717/ https://www.ncbi.nlm.nih.gov/pubmed/31950142 http://dx.doi.org/10.1093/jjco/hyz208 |
| work_keys_str_mv | AT iwatahiroji corrigendumtosubgroupanalysisofjapanesepatientsinaphase3studyofatezolizumabinadvancedtriplenegativebreastcancerimpassion130 AT inouekenichi corrigendumtosubgroupanalysisofjapanesepatientsinaphase3studyofatezolizumabinadvancedtriplenegativebreastcancerimpassion130 AT kanekokoji corrigendumtosubgroupanalysisofjapanesepatientsinaphase3studyofatezolizumabinadvancedtriplenegativebreastcancerimpassion130 AT itoyoshinori corrigendumtosubgroupanalysisofjapanesepatientsinaphase3studyofatezolizumabinadvancedtriplenegativebreastcancerimpassion130 AT tsugawakoichiro corrigendumtosubgroupanalysisofjapanesepatientsinaphase3studyofatezolizumabinadvancedtriplenegativebreastcancerimpassion130 AT hasegawaayumi corrigendumtosubgroupanalysisofjapanesepatientsinaphase3studyofatezolizumabinadvancedtriplenegativebreastcancerimpassion130 AT nakagawashintaro corrigendumtosubgroupanalysisofjapanesepatientsinaphase3studyofatezolizumabinadvancedtriplenegativebreastcancerimpassion130 AT kuratomihiroyasu corrigendumtosubgroupanalysisofjapanesepatientsinaphase3studyofatezolizumabinadvancedtriplenegativebreastcancerimpassion130 AT tamurakenji corrigendumtosubgroupanalysisofjapanesepatientsinaphase3studyofatezolizumabinadvancedtriplenegativebreastcancerimpassion130 |